keyword
MENU ▼
Read by QxMD icon Read
search

Lenalinomide

keyword
https://www.readbyqxmd.com/read/24658665/new-agents-for-prostate-cancer
#1
REVIEW
N Agarwal, G Di Lorenzo, G Sonpavde, J Bellmunt
The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized by the arrival of multiple novel agents in the past 2 years. Immunotherapy in the form of sipuleucel-T, androgen axis inhibitors, including abiraterone acetate and enzalutamide, a chemotherapeutic agent, cabazitaxel, and a radiopharmaceutical, radium-223, have all yielded incremental extensions of survival and have been recently approved. A number of other agents appear promising in early studies, suggesting that the armamentarium against castrate-resistant prostate cancer is likely to continue to expand...
September 2014: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/24506467/efficacy-and-safety-of-lenalinomide-combined-with-rituximab-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma
#2
Vadim Ivanov, Diane Coso, Bruno Chetaille, Benjamin Esterni, Daniel Olive, Therese Aurran-Schleinitz, Jean Marc Schiano, Anne-Marie Stoppa, Florence Broussais-Guillaumot, Didier Blaise, Reda Bouabdallah
Initial clinical trials demonstrated that lenalidomide monotherapy has a significant activity against some subtypes of lymphoma, but in diffuse large B-cell lymphoma (DLBCL) its activity is limited. The combination of lenalidomide with rituximab may be a promising therapeutic strategy. We retrospectively analyzed clinical outcomes in 17 patients with relapsed/refractory (R/R) DLBCL treated with lenalidomide, 25 mg/day for 21/28 days and rituximab, 375 mg/m(2) on day 7 of every lenalidomide cycle, for a maximum of 12 months...
November 2014: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/23699614/recurrent-acute-eosinophillic-pneumonia-in-a-patient-with-hodgkin-s-lymphoma
#3
Michael Fingerhood, Kevin Felner
SESSION TYPE: Cancer Student/Resident Case Report PostersPRESENTED ON: Tuesday, October 23, 2012 at 01:30 PM - 02:30 PMINTRODUCTION: Hodgkin's Lymphoma (HL) is commonly associated with peripheral eosinophilia but not eosiniophilic organ infiltration. We report a case of an HL patient suffering two discrete episodes of Acute Eosinophilic Pneumonia (AEP).CASE PRESENTATION: A 34 year-old man with refractory HL (to chemotherapies and bone-marrow transplant, currently on Lenalinomide), intermittent eosinophilia and AEP (17 months prior due to Gemcitabine) presented with complaints of fever, dyspnea and productive cough...
October 1, 2012: Chest
https://www.readbyqxmd.com/read/23429354/the-spectrum-of-type-i-cryoglobulinemia-vasculitis-new-insights-based-on-64-cases
#4
Benjamin Terrier, Alexandre Karras, Jean-Emmanuel Kahn, Guillaume Le Guenno, Isabelle Marie, Lucas Benarous, Adeline Lacraz, Elisabeth Diot, Olivier Hermine, Luc de Saint-Martin, Pascal Cathébras, Véronique Leblond, Philippe Modiano, Jean-Marc Léger, Xavier Mariette, Patricia Senet, Emmanuelle Plaisier, David Saadoun, Patrice Cacoub
Type I cryoglobulinemia vasculitis (CryoVas) is considered a life-threatening condition; however, data on the characteristics and outcome are scarce. To analyze the presentation, prognosis, and efficacy and safety of treatments of type I CryoVas, we conducted a French nationwide survey that included 64 patients with type I CryoVas between January 1995 and July 2010: 28 patients with monoclonal gammopathy of unknown significance (MGUS) and 36 with hematologic malignancy.Type I monoclonal CryoVas was characterized by severe cutaneous involvement (necrosis and ulcers) in almost half the patients and high serum cryoglobulin levels, contrasting with a lower frequency of glomerulonephritis than expected...
March 2013: Medicine (Baltimore)
https://www.readbyqxmd.com/read/22045188/rapid-in-vivo-testing-of-drug-response-in-multiple-myeloma-made-possible-by-xenograft-to-turkey-embryos
#5
Y Farnoushi, M Cipok, S Kay, H Jan, A Ohana, E Naparstek, R S Goldstein, V R Deutsch
BACKGROUND: The best current xenograft model of multiple myeloma (MM) in immune-deficient non-obese diabetic/severe-combined immunodeficient mice is costly, animal maintenance is complex and several weeks are required to establish engraftment and study drug efficacy. More practical in vivo models may reduce time and drug development cost. We recently described a rapid low-cost xenograft model of human blood malignancies in pre-immune turkey. Here, we report application of this system for studying MM growth and the preclinical assessment of anticancer therapies...
November 22, 2011: British Journal of Cancer
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"